Ketamine One Partners with Cognetivity Neurosciences in Collaborative Clinical Study on Depression and PTSD
Ketamine One Capital Limited (KONEF) announces a partnership with Cognetivity Neurosciences to develop assessments for depression and post-traumatic stress disorder (PTSD). Two clinical studies are set to begin in early 2022, utilizing Cognetivity's Integrated Cognitive Assessment (ICA) technology, already deployed in Ketamine One's clinics. This collaboration aims to validate ICA's effectiveness in monitoring cognitive changes during treatment, enhancing Ketamine One's position in the growing mental health market, which is expected to exceed USD 13 billion by 2027.
- Partnership with Cognetivity expected to enhance treatment for depression and PTSD, tapping into a growing market.
- Clinical studies approved by Institutional Review Board, indicating regulatory compliance.
- Utilization of ICA technology may lead to novel intellectual property and new product development.
- None.
Research Study Follows Ketamine One’s Deployment of Cognetivity’s ICA in its North American Clinics and is Expected to Open Up Novel, Tailored Use Cases in the Burgeoning Mental Health Market
VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: 6FC), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it is entering into a collaborative partnership with Cognetivity Neurosciences Ltd. (CSE: CGN; OTCQB: CGNSF; FWB: 1UB) (“Cognetivity”) to study and develop assessments for depression and post-traumatic stress disorder (“PTSD”).
In the initial stage of the partnership, Cognetivity and Ketamine One will partner on two separate clinical studies, one for depression and the second for PTSD. Protocols for both studies have received Institutional Review Board (“IRB”) approval and patient recruitment is expected to occur in early 2022. Ketamine One’s wholly owned subsidiary, KGK Science Inc., will lead the study, while Cognetivity will lead the analysis.
Ketamine One is a next-generation health and wellness company focused on transforming the treatment of mental health by providing ketamine-assisted therapy and psychedelic medicines. Based in Canada and operating clinics throughout North America, the firm is dedicated to building the critical infrastructure needed to provide potentially breakthrough and life-changing treatments for conditions such as anxiety, PTSD, chronic pain and addiction.
Cognetivity’s Integrated Cognitive Assessment (“ICA”) technology has already been deployed throughout Ketamine One’s network of clinics in North America after the two companies entered into a commercial agreement earlier this year. In the latest phase of their collaboration, the ICA will be used to monitor changes in patients’ cognitive ability as they undergo ketamine-assisted treatment for depression and PTSD.
The clinical studies will add to the extensive body of data validating the ICA’s use as a cognitive testing tool. It has already been widely deployed in clinical care, from North America and the Middle East to clinics in the UK’s National Health Service. The project will also generate novel intellectual property regarding the ICA’s predictive and long-term monitoring capabilities – not only on a stand-alone basis, but in combination with additional variables, including data from wearable devices, to support the creation of dedicated new products for specialist care in the areas of depression and PTSD.
It is well documented that there is vast potential for improvement in the treatment of such conditions. According to the World Health Organization, mental health disorders account for
Management Commentary
“We’re delighted to be extending our relationship with Cognetivity through this exciting new research project,” said Adam Deffett, Interim CEO of Ketamine One. “Depression and PTSD are sadly very common conditions and existing approaches to treating them leave a lot to be desired. With the crucial involvement of the ICA, this study will further demonstrate the power of our therapies as we pursue our goal of changing how mental health is treated across North America.”
Also commenting on the announcement, Dr. Sina Habibi, CEO of Cognetivity, said, “It’s great to be working with Ketamine One on these clinical studies. We are very excited about obtaining high-quality clinical validation data on the use of the ICA to assess and monitor patients with depression and PTSD, and developing exciting new technology to better serve this huge market. These disease areas represent important use cases for the ICA beyond its core application as a device for dementia detection and diagnosis, and the fact that it can transition so smoothly into this new space confirms the strength of its fundamental capabilities and the ongoing global need for much-improved cognitive testing across a huge number of areas.”
ABOUT COGNETIVITY NEUROSCIENCES LTD.
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK and Europe, with regulatory approval for other regions planned for 2022.
For more information, please visit: www.cognetivity.com or contact: info@cognetivity.com.
ABOUT KETAMINE ONE
KetamineOne Capital Limited (formerly Myconic Capital Corp.) is a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments. It is working to provide the critical infrastructure needed to develop and deliver breakthrough mental health treatments. Currently, Ketamine One has a network of clinics across North America, with plans to further consolidate the highly fragmented industry. KGK Science Inc. is the Company’s wholly owned contract research division, which places it at the forefront of premium clinical research based on the subsidiary’s history and extensive experience in pharmaceuticals, cannabis, and the emerging psychedelic medicine industries. As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.
On behalf of:
KETAMINE ONE
"Adam Deffett"
Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor Relations
Tel: 1-844-PHONE-K1 (1-844-746-6351)
Email: IR@ketamine.one
Web: www.ketamine.one
Twitter: @KetamineOne
Notice Regarding Forward-Looking Information:
This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.
The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
Endnotes
- (2021, April). Post-Traumatic Stress Disorder (PTSD) Therapeutics. Global Industry Analysts. Retrieved December 1, 2021, from https://www.marketresearch.com/Global-Industry-Analysts-v1039/Post-Traumatic-Stress-Disorder-PTSD-14405453/
- (n.d.) Anxiety Disorders and Depression Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics), By Indication (Anxiety and Depression), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027. Fortune Business Insights. Retrieved December 1, 2021, from https://www.fortunebusinessinsights.com/anxiety-and-depression-treatment-market-102787
SOURCE: KetamineOne Capital Limited
FAQ
What is the purpose of the clinical studies announced by Ketamine One (KONEF)?
When are patient recruitments expected to begin for Ketamine One's clinical studies?
What technology will be used in the studies for depression and PTSD?
What is the market potential for PTSD therapeutics?
